TCGA-NC-A5HJ-01A-11R-A26W-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.520
- INTERFERON_GAMMA_RESPONSE+0.400
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.310
- PANCREAS_BETA_CELLS+0.310
- ALLOGRAFT_REJECTION+0.290
- SPERMATOGENESIS+0.260
- COMPLEMENT+0.210
- MITOTIC_SPINDLE+0.190
- BILE_ACID_METABOLISM+0.180
Top 10 suppressed
- UNFOLDED_PROTEIN_RESPONSE-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- MYC_TARGETS_V2-0.420
- GLYCOLYSIS-0.380
- PROTEIN_SECRETION-0.360
- MYC_TARGETS_V1-0.340
- TGF_BETA_SIGNALING-0.320
- MTORC1_SIGNALING-0.300
- OXIDATIVE_PHOSPHORYLATION-0.290
- P53_PATHWAY-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.805 |
| 2 | R218 | — | — | 0.804 |
| 3 | DRR168597 | — | — | 0.796 |
| 4 | TCGA-CN-A6V6-01A-12R-A34R-07 | — | — | 0.779 |
| 5 | TCGA-BA-5559-01A-01R-1514-07 | — | — | 0.761 |
| 6 | s0122145 | — | — | 0.760 |
| 7 | ERR2208913 | — | — | 0.757 |
| 8 | SRR1516037 | — | — | 0.745 |
| 9 | C3N-02234 | — | cohortA1 | 0.743 |
| 10 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |